| A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer. |
Nature et Objective:
This Phase 1 study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-969 in adult patients with metastatic castration-resistant prostate cancer. The study includes a dose-escalation phase designed to determine the recommended dose and characterize the treatment’s safety profile and antitumor activity. (Study sponsored by AbbVie)
Stade de la Maladie: Métastatique
Organe: Prostate
Maladie: mCRPC